Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience

Vrontis, Konstantinos; Economidou, Sofia C.; Fotopoulos, George

doi:10.1080/07357907.2021.1988962

Cited by 3 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To further improve the prognosis in patients with LCNEC, we observed the e cacy of immunotherapy plus chemotherapy versus chemotherapy in these patients. Consistent with the retrospective study of ICIs alone [11,[22][23][24][25][26][27], our ndings also indicated a potential clinical bene t in patients treated with immunotherapy plus chemotherapy compared to chemotherapy (26.31 months VS. 16.95 months, P = 0.675). Owing to the data gap between the two groups and considering the bias caused by the patients' ECOG PS and tumor stage, the results of PSM showed a statistically signi cant difference (26.31 vs. 13.56 months, P = 0.041), which may better re ect the gap in clinical e cacy between the two groups.…”

Section: Discussionsupporting

confidence: 89%

“…In 2020, a retrospective study of 125 patients with LCNEC further demonstrated a longer survival bene t (mOS: 12.4 months vs. 6.0 months) in ICIs alone compared with those who did not receive ICIs [23]. In addition, several other retrospective studies have yielded similar results [11,22,[24][25][26][27]. Shirasawa et al con rmed that ICIs positively affect patients with LCNEC regardless of PD-L1 expression.…”

Section: Discussionmentioning

confidence: 97%

“…Immune checkpoint inhibitors (ICIs) are a class of monoclonal antibodies that mediate treatment properties by blocking immune checkpoints [18], including programmed death receptor 1 (PD-1)/programmed death receptor-ligand 1 (PD-L1), cytotoxic T lymphocyte-associated protein 4, and other types of antibodies [19,20]. ICIs have demonstrated signi cant survival bene ts in various tumor types [21], and retrospective studies have reported that ICIs alone are effective in patients with LCNEC [11,[22][23][24][25][26][27]. However, in the tumor microenvironment (TME), the interaction between immune cells and nonimmune cells has led to the e cacy of ICIs not achieving the expected effect [21].…”

Section: Introductionmentioning

confidence: 99%

“…Studies have con rmed that the combination of surgery, chemotherapy, radiotherapy, targeted therapy, and other treatment modalities with ICIs can have a synergistic effect [28][29][30]. Currently, a limited number of studies [11,[22][23][24][25][26][27] have been published on the use of ICIs in patients with LCNEC; therefore, further research is needed to determine the appropriate treatment timing, treatment plan, and other in uencing factors. Based on the actual clinical applications and the complexity of TME, this study aimed to evaluate the clinical e cacy and safety of immunotherapy plus chemotherapy in patients with LCNEC.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and safety of immunotherapy plus chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma

Li,

Zhang,

Zhao

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose This study aimed to assess the efficacy and safety of immunotherapy plus chemotherapy for pulmonary large cell neuroendocrine carcinoma (LCNEC). Methods We retrospectively analyzed the data of 124 patients with LCNEC hospitalized at Shandong Cancer Hospital between January 2018 and December 2022. Among these, 45 and 79 individuals were in the immunotherapy plus chemotherapy and chemotherapy groups, respectively. Baseline data of the two groups were balanced using propensity score matching (PSM), and the Kaplan–Meier survival curve was used to evaluate the clinical efficacy of the treatment regimen. Results The median follow-up period was 33.05 months. Compared with that in the chemotherapy group, the median overall survival (OS) in patients in the immunotherapy plus chemotherapy group showed a trend of clinical benefit (26.31 vs. 16.95 months, hazard ratio [HR] = 0.907, P = 0.675). After the PSM, the median OS (26.31 vs. 13.56 months, HR = 0.605, P = 0.041) showed statistically significant differences between the two groups. Univariate and multivariate analyses found that patient age (P < 0.001) may be related to prognosis. In the immunotherapy plus chemotherapy group, the overall response rate was 46.7%, the disease control rate was 84.4%, and the median progression-free survival was 7.95 months (95% CI: 5.5–14.8). Simultaneously, Patients with early-stage LCNEC may obtain longer PFS by choosing immunotherapy plus chemotherapy in the first or second line. Conclusion Patients with LCNEC receiving immunotherapy plus chemotherapy may have better outcomes, with a tolerable safety profile without life-threatening adverse events.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of immunotherapy plus chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma

Li,

Zhang,

Zhao

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…(47) Vrontis et al suggested that treatment and management of patients with advanced LCNEC could be achieved with SCLC approaches, such as platinum-etoposideatezolizumab chemotherapy, which can improve prognosis. (48) Additional prospective randomized controlled studies are needed.…”

Section: Advantages and Shortcomingsmentioning

confidence: 99%

Risk factors, survival analysis, and nomograms for distant metastasis in patients with primary pulmonary large cell neuroendocrine carcinoma: A population-based study

Song

Zou

2022

Front. Endocrinol.

View full text Add to dashboard Cite

IntroductionPulmonary large cell neuroendocrine carcinoma (LCNEC) is a rapidly progressive and easily metastatic high-grade lung cancer, with a poor prognosis when distant metastasis (DM) occurs. The aim of our study was to explore risk factors associated with DM in LCNEC patients and to perform survival analysis and to develop a novel nomogram-based predictive model for screening risk populations in clinical practice.MethodsThe study cohort was derived from the Surveillance, Epidemiology, and End Results database, from which we selected patients with LCNEC between 2004 to 2015 and formed a diagnostic cohort (n = 959) and a prognostic cohort (n = 272). The risk and prognostic factors of DM were screened by univariate and multivariate analyses using logistic and Cox regressions, respectively. Then, we established diagnostic and prognostic nomograms using the data in the training group and validated the accuracy of the nomograms in the validation group. The diagnostic nomogram was evaluated using receiver operating characteristic curves, decision curve analysis curves, and the GiViTI calibration belt. The prognostic nomogram was evaluated using receiver operating characteristic curves, the concordance index, the calibration curve, and decision curve analysis curves. In addition, high- and low-risk groups were classified according to the prognostic monogram formula, and Kaplan–Meier survival analysis was performed.ResultsIn the diagnostic cohort, LCNEC close to bronchus, with higher tumor size, and with higher N stage indicated higher likelihood of DM. In the prognostic cohort (patients with LCNEC and DM), men with higher N stage, no surgery, and no chemotherapy had poorer overall survival. Patients in the high-risk group had significantly lower median overall survival than the low-risk group.ConclusionTwo novel established nomograms performed well in predicting DM in patients with LCNEC and in evaluating their prognosis. These nomograms could be used in clinical practice for screening of risk populations and treatment planning.

show abstract

Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma

Shi,

Wei,

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background Lung large-cell neuroendocrine carcinoma (L-LCNEC) is a rare and highly aggressive neuroendocrine tumor. There is currently no standard therapeutic regimen, and systemic chemotherapy results in poor prognosis. Due to the rarity of L-LCNEC, the efficacy and safety of immune checkpoint inhibitors (ICIs) remain unclear. Methods This study included 34 L-LCNEC patients administered ICIs at Zhejiang Cancer Hospital, from February 6, 2018 to February 6, 2023. The treatment responses were evaluated. Fisher’s exact test was used to compare categorical variables, and the Kaplan-Meier method was used for survival analyses. Cox regression was used for multivariate analysis. Results The objective response rate (ORR) of 34 patients was 29.4%, the disease control rate (DCR) was 82.4%, the median progression-free survival (PFS) was 6.30 months, and the median overall survival (OS) was 14.77 months. The ORRs of combined LCNEC (n=7) and pure LCNEC (n=27) were 14.3% and 33.3%; the DCRs were 100% and 77.8%; the median PFSs were 12.48 and 5.6 months (P=0.032); and the median OSs were 21.27 and 14.73 months, respectively (P=0.233). The observed incidence of immune-related adverse events (irAEs) was 61.8%, primarily occurring in grades 1/2 (58.8%) and grade 3 (5.9%). Elevated aminotransferases (14.7%), pneumonia (8.8%), and fatigue (8.8%) were the most common irAEs. Conclusions ICIs treatment showed efficacy and safety in advanced L-LCNEC, with the potential for greater benefits in the combined LCNEC subtype.

show abstract

Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience

Cited by 3 publications

References 25 publications

Efficacy and safety of immunotherapy plus chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma

Efficacy and safety of immunotherapy plus chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma

Risk factors, survival analysis, and nomograms for distant metastasis in patients with primary pulmonary large cell neuroendocrine carcinoma: A population-based study

Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma

Contact Info

Product

Resources

About